Filing Flows › Guardant Health (GH) › Q1 2026
Guardant Health (GH) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Guardant Health (GH) reported revenue of $302M for the first quarter 2026 (Q1 2026), +48% from a year earlier and +7% from the quarter before. Operating margin was -40.2%, net loss $112M (37.2% of revenue).
Guardant Health, Q1 2026: revenue $302M (+48% year over year), operating margin -40.2%, net loss $112M, operating cash flow −$65.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $302M | +7% | +48% |
| Operating profit | −$121M | — | — |
| Net earnings | −$112M | — | — |
| Operating cash flow | −$65.6M | — | — |
What changed
Revenue was $301.7M in Q1 2026, up 48% year over year and up 7% from the previous quarter. Oncology was the largest line at 68% of revenue. Oncology added $54.4M year over year (up 36%), 55% of the total change.
Operating costs exceeded revenue by $121.3M, an operating margin of -40.2%. Total costs grew 34% against revenue growth of 48%. The fastest-growing cost line was Sales & marketing (+62%). The quarter ended with a net loss of $112.1M, narrower than the previous quarter's $128.5M loss.
Operating cash flow was −$65.6M. Non-cash charges added back $9.4M of depreciation and amortization and $47.6M of share-based compensation. Working capital and other items used $10.6M. Capital expenditures of $5.6M exceeded it, leaving free cash flow of −$71.2M.
Questions
What was Guardant Health's revenue in the first quarter 2026?
Guardant Health (GH) reported revenue of $302M for the first quarter 2026 (Q1 2026), +48% from a year earlier and +7% from the quarter before.
Was Guardant Health profitable in the first quarter 2026?
Operating loss was $121M (-40.2% of revenue) and net loss $112M.
Source: Guardant Health 10-Q on SEC EDGAR.